Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Sweden
Finland
Denmark
Norway
Latest
Trending
Followed

Oncopeptides, Audiocast, Q1'26

By Inderes5/13/2026, 7:00 AM
Oncopeptides

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Sofia Heigis
00:01 - 02:23

Welcome to the Oncopeptides webcast for the first quarter of 2026. Please note the disclaimer regarding forward-looking statements. Today's presentation is led by myself, Sofia Heigis, and our CFO Henrik Bergentoft. We delivered net sales of 25.4 million in Q1 2026, a 91% increase compared to Q1 2025. Following the rights issue we announced in conjunction with our last quarterly update, the company held a cash position of 205.2 million SEK by the end of Q1. We remain on track to reach positive cash flow by 2027. During the quarter, we announced and completed a rights issue of approximately 200 million SEK. I would like to take this opportunity to thank all our shareholders, new and old, who chose to participate in the rights issue. I would also like to thank Healthcap, our main owner, for their continued support and trust in Oncopeptides. We secured Fast Track designation for our window-of-opportunity clinical study in glioblastoma, which emphasizes the high unmet need for this very difficult-to-treat tumor. Additionally, we continue to underscore Pepaxti's position in the treatment landscape through real-world data. During Q1, data was published in the European Journal of Hematology, which reinforces Pepaxti's role in today's treatment landscape. Finally, we initiated the MARINA study to strengthen real-world evidence for Pepaxti in Germany in partnership with I o medico. Well worth mentioning in the events after the period is the announcement we made on Monday that we are intending to submit a Type II variation to expand Pepaxti's label into the third-line, in addition to our current label in fourth-line. We went over the announcement in detail on Monday, and I will give a short recap later during this call. Now over to Henrik for a summary of the financials.

Henrik Bergentoft
02:24 - 04:39

Thank you Sofia. We're executing with focus and discipline. Today's update reinforces the strength of our scalable model. The quarter reflects strong commercial traction and tight cost management, positioning us well to convert growth into improving leverage while staying deliberate on capital allocation. Displaying highlights from Q1 revenue growth of 91% year over year is a clear signal that demand is accelerating and our commercial engine is working. A 99% gross margin highlights the inherent scalability of the business model and the quality of our revenue base. Operating expenses down 11% year over year show we can grow while remaining cost conscious. Setting up an attractive operating leverage ahead. We continue to invest with precision in commercialization. Activities are focused on high-potential European markets, which support sustainable expansion. General and administrative reductions demonstrate strong internal cost control, and the decline in R&D costs reflects prioritization while keeping innovation moving forward. We're optimizing near-term spend while advancing the preclinical portfolio, sharpening focus on glioblastoma as the most important value driver. Ending the quarter with 205 million in cash provides a solid foundation and meaningful execution runway. The successful rights issue, adding 167 million net, strengthens flexibility to deliver on our plans and pursue attractive opportunities. All taken together, growth, margin, strength, disciplined costs, and enhanced liquidity. We're well positioned to create shareholder value in the quarters ahead. And with that, back to you, Sofia.

Sofia Heigis
04:39 - 24:40

Thank you Henrik. We are building the foundation of Oncopeptides from our commercialization of Pepaxti in Europe. Mid-Term. We are working to add revenue from other geographies. And long term, we are developing our pipeline with current focus on our PDC platform that, as a platform, has a transformative potential for the company by addressing difficult-to-treat tumors such as multiple myeloma, AML, and glioblastoma, to mention a few. After a slower than expected end to 2025, we are back to a strong growth momentum in Europe, where our current labels stand for a market potential of 1.5 billion SEK. Our pipeline targets the glioblastoma market, which is anticipated to grow due to a very high unmet need, with an estimated global market potential exceeding $8 billion. Looking at some of the announcements in Q1 and how they affect this investment case, we conclude that we have made progress in most areas. As said, we earlier this week announced our intended application to enter the third line of treatment, which would significantly increase the addressable market for Pepaxti. We have received the first feedback from regulatory authorities on our window of opportunity study, and we are on track to initiate the first clinical study and treat the first patient with glioblastoma this summer. Our ambition to conclude a partnership in Japan remains, and we are also working on other geographies in parallel. I will, during the presentation, give you an update on our progress during the quarter. Before I go into detail for the different European markets, a look at our sales trajectory. We have experienced some seasonal challenges at the beginning of the year, and we continue to have challenges in Spain with an underperformance during Q1. Despite this, we demonstrated an overall encouraging development, which was primarily due to a strong continued uptake in Italy and an acceleration and step-up from Germany in the second half of the quarter. These are our two largest markets, and it's encouraging to see how they are taking off. It should be mentioned that Greece continues to deliver and as we anticipated, we got the volumes missing in Q4 ordered in Q1. All in all, we are satisfied with the development both in Germany, Italy, and Greece. While we need to catch up in Spain. Approximately 800 patients have been treated since EMA approval in 2022, and the clinical profile of Pepaxti is continuously being confirmed by real-world data published by independent authors. The Pepaxti inclusion in the EHA EMN guidelines with a one B recommendation is important when driving awareness, advocacy and the right positioning of Pepaxti in what has become a complex treatment landscape that is difficult to navigate for many prescribers. We continue to build on the growing body of real-world evidence supporting Pepaxti following its use by doctors across Europe. Let's have a closer look. I commonly refer to the fact that our launch is built on a positive clinical experience. So let me walk you through some of the real-world data published that confirms my statement. Important when looking at real-world data, it always has limitations as it is retrospective, but it does complement clinical trials, and it is gathered from the current treatment landscape and demonstrates real-world safety and effectiveness. To put the data into context, I wish to remind you that our current label is based on the efficacy data of the HORIZON study, with 29% overall response rate in our target population. This level is considered clinically meaningful in this late stage population, with a median of prior five lines of treatment. So, looking at the overall picture, these retrospective studies that are all published by external authors confirm Pepaxti effectiveness and that the product has a manageable safety profile in heavily pretreated patients during the first quarter. The first data from Italy was published, which is the second publication from Europe, on how Pepaxti can complement immunotherapy. The Italian data included 17 patients and demonstrated a strong overall response rate of 41%. Interestingly, the response to subsequent immunotherapy treatment was considered clinically meaningful by the authors, as the majority of patients achieved a very good partial response or better. This means Pepaxti can serve as a bridge between two different immunotherapies, a position that is becoming more and more important. Furthermore, the Italian data was the first published case of Melflufen as bridging to CAR T with an encouraging complete response as outcome. Another important real-world data set from Spain, published in 2025, is the other significant data set from Europe. The Spanish data set includes 19 patients and was generated in an even more frail and late-line population than the Italian patient population. The Spanish data demonstrates an overall response rate of 28%. This is very similar to the ORR in our Horizon study, which means that the level of efficacy from our clinical trial data seems valid. Also in today's treatment landscape, which is important to prescribers. We have interesting case studies being published that confirm the therapy is well tolerated in patients with severe renal insufficiency, which is important as many of our patients are old and do have comorbidities. Finally, the Long-Term Responders publication includes patients for whom Pepaxti is making a really big difference. The long term responders published have received between 46 and 83 cycles of treatment, which is important as it is informing clinical decision making and generates confidence in Pepaxti, as well as supports the clinical proof of concept for the entire PDC platform. The long-term responders published have received between 46 and 83 cycles of treatment, which is important as it informs clinical decision-making and generates confidence in Pepaxti, as well as supports the clinical proof of concept for the entire PDC platform. So in summary, what we see from our RWD data, Pepaxti does serve as a strategic option for patients unable to receive immunotherapy due to frailty or comorbidities. It is an ideal bridge between immune-based therapies to allow for T-cell recovery. It remains a proven alternative for patients who have relapsed after BCMA CAR T therapies. Now, let's move for a closer look at the performance of our different key markets during Q1. Germany demonstrated strong growth, particularly in the second half of the quarter. As you may recall, we restructured, reduced, and focused our German team on high potential customers in areas with a strong momentum. It is really encouraging to see the effect of these efforts, with a significant step up in new patients starting treatment during one month. In fact, we have seen the number of new patients in March double versus January, and January was at the level of the average month in 2025. With the cost reductions and acceleration in sales, we are on track to reach country-level profitability in Germany during 2026. Finally, one important announcement we made for Germany in the first quarter was the partnership with IO Medical for the MARINA study, which is an investigator-initiated prospective non-interventional study that is designed to evaluate the real-world effectiveness, safety, and treatment patterns of Pepaxti in our current label population in Germany. IO Medical is a highly sought after partner, as they have proven effectiveness in executing real-world studies. Partly due to that, they have access to the largest network of office-based physicians. As this graph shows, we are continuing to grow our prescriber base in Germany. Let's move to Italy. During Q1, we achieved our target of close to 100% regional access in Italy. The strong uptake is built from a strong foundation with a positive clinical experience, a more centralized prescriber base with more patients per prescriber. And of course, due to an excellent team who has been working really hard to launch and utilize the positive momentum. Pepaxti is currently gaining a strong position in the fourth line in Italy, really complementing immunotherapy, which is exactly the position we are aiming for in all our markets with our current label. The challenging environment in Spain continued during the first quarter. While we saw a small step up in March, the quarter was, all in all, quite far below expectations. The doctor strike we commented on in our last quarterly updates continues to influence, resulting in limited access to physicians for Pharma and delayed approval from committees regarding the treatment of late-stage patients. The innovative Multiple Myeloma market segment is overall underperforming in Spain, and this, together with limited access, has created very high competitive pressure between companies during the first quarter. Being a small company in that environment, we have to focus to succeed in a market that has become difficult to navigate. One example of focus is that we have been in frequent contact with all the key opinion leaders, and we have together initiated different publications and projects that will support us to position Pepaxti versus immunotherapy to ensure we can catch up on sales in Spain. We will, in fact, see some very interesting data to support the market being published. This will take place the upcoming weekend at the Congress in Paris. Strengthened by the potential entry into third line, we will reassess the overall market opportunity in the rest of Europe. And regarding Central Eastern Europe, we have always aimed for a partnership and have advanced our discussions during Q1. We are continuously looking into options for the rest of Europe. This Monday, we announced our intention to expand Pepaxti into the third line of treatment, and I will now provide a summary. The rationale behind our decision rests on four key pillars: market expansion. Extended exposure. Clinical value and pricing viability. We aim to move into the third line and reach less refractory patients, which would at least double the number of addressable patients in Europe compared to our current label. Clinical data demonstrates that treatment cycles in the third line setting are expected to double on average compared to our current label. This submission is built on the Phase three Ocean study data, which EMA previously has deemed approvable. What makes us take this decision now is that our assessment of the current treatment landscape indicates that we can now expand without compromising our innovative price level. To give you an understanding of this decision down to patient level, this chart illustrates the typical journey of multiple myeloma patients from initial diagnosis through successive severe relapses and given all the new treatment options, multiple myeloma has become a marathon with many lines of treatment rather than a short sprint. Today, there is no cure for multiple myeloma, and as you can see, each relapse is accompanied by an increase in tumor burden, meaning the tumor becomes more and more aggressive and difficult to treat. Partly triggered by that, the tumor has to fight against many different modes of action in the earlier lines, which makes it a tough warrior and more and more difficult to beat. Our current indication is represented by the orange block on the far right, serving patients in advanced disease, specifically those in the fourth line of therapy and beyond who are Triple Class Refractory. At this late stage, the disease burden has already undergone rapid acceleration, and the patients are commonly both old and have become frail by both the tumor, the side effects from previous treatments, and comorbidities. Our goal with this Type II variation is to move that orange block to the left, as shown here. If we expand into the third line, we can, in addition to our current population in fourth line and beyond, also treat patients earlier in their disease course. This is a comparison between our current and potential future indication. Our current indication is for patients who have received at least three prior lines and are Triple Class Refractory. The potential future indication would target patients who have received at least two prior lines and are refractory to lenalidomide and the last line of therapy. This broader population allows us to bring the benefits of Pepaxti to patients earlier in the treatment journey. We plan to submit the Type II variation to EMA in the coming months, and we are currently preparing the regulatory documentation needed to submit the application. Initial regulatory feedback is anticipated in the second half of 2026, with a final decision from the European Commission expected in the first half of 2027. We are also starting to prepare market access processes that can be formally initiated post EC decision. This process looks different in various markets, and we will update the financial market on more specifics as we proceed. Oncopeptides is continuously working to maximize our European sales potential. For more information, I would like to refer you to our webcast held on Monday, which is available on our website and provides much more information about the historical context and scientific data. Now let's move outside of Europe. Our negotiations in Japan have taken longer than expected, with several delays during the process that have been out of our control. The treatment landscape is evolving, and from our perspective, the need for a PDC becomes more and more evident in the way that the Pepaxti mode of action complements the immunotherapy. We are eager to conclude a deal to bring the benefit of the PDCs to Japanese patients, which is why we have taken the decision to open up for parallel discussions with multiple partners again. Regarding partnerships for other parts of the world, we have always seen this as opportunistic. In the beginning of the year, we hoped for first named patient sales in the Middle East due to some progress in our partner discussions last year. However, currently the situation is unstable in the region, and it is difficult to predict if that is still possible. Regarding our pipeline, we are now focused on our glioblastoma project and are looking for external collaborations to advance PDCs in other indications. Our PDC platform includes the assets OPD5 and OPDC3. The PDC platform is built on a smart innovation that, through distribution, concentrates killing power inside the cell while sparing healthy tissue. It is specifically engineered to overcome resistance pathways such as p53 mutations that often stop traditional drugs. It is now also clinically validated by approximately 800 patients treated and over 25 million in sales. This quarter shows that while plenty of potential remains, Pepaxti is being used today and is making a difference for both patients and their relatives. We have taken the first step to broaden the use of PDCs into more difficult-to-treat cancer by targeting new markets like glioblastoma. In the first glioblastoma study, we are working hard to initiate what we call a window of opportunity study. It is a focused study of approximately ten patients to prove human blood-brain barrier penetration. We do this because the blood-brain barrier prevents most drugs from reaching brain tumors, but our PDCs have shown a unique ability to cross this barrier in preclinical models, and we wish to confirm this in humans before we proceed to Phase 1. It is a fairly low investment that can generate the human proof-of-concept data needed to progress towards the market, with a very high unmet need estimated to grow into an 8 billion USD global market potential. The glioblastoma program has true potential to transform Oncopeptides into a multi-indication global player. In the first quarter, we achieved regulatory agreement with Swedish and Norwegian agencies for the Window of Opportunity study. We were granted a fast track designation by the Norwegian DMP, enabling an accelerated review process that addresses this life threatening condition. We have now received the first questions and are still on track to initiate the study during the coming summer. To summarize, we have achieved 91% year over year growth and have a fully approved product with expansion plans that could double the number of addressable patients in Europe and the average number of treatments they go through compared to our current label. We are also strategically expanding through partnerships and targeting major unmet needs like glioblastoma. With that, I would like to thank you for listening, and let's open up for questions.

Operator
24:42 - 24:59

If you wish to ask a question, please dial pound key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound key six on your telephone keypad. The next question comes from Richard Romanius from Redeye. Please go ahead.

Richard Romanius
25:01 - 25:21

Hello. Good. Good morning. My first question on operating costs: Is this a new, lower cost base compared to previous quarters? I can calculate it was around 10 million lower. Is this the new cost base going forward?

Henrik Bergentoft
25:24 - 26:25

Yes. Thank you, Richard, for that question. Well, as we announced in conjunction with the release of the year-end report, we have made adjustments to the organization, sharpening both our commercial organization, mainly in Germany, and also our R&D organization and how we conduct R&D activities. So, you are to expect a full year cost for 2026 that will be somewhat below the 2025 full year cost. But, just as a reminder, there is certain seasonality to our cost base as well, where typically the second quarter and the fourth quarter are higher, mainly due to increased Congress activities compared to Q1 and Q3. So, in summary, yes, you can expect a lower cost for the full year, but also expect seasonality in the cost base.

Richard Romanius
26:28 - 26:41

Very well. My question for Sofia, could you say something about the trend in Q2 for sales?

Sofia Heigis
26:43 - 27:04

So thank you and good morning. For that question. We would like to refrain from commenting on Q2, but what I can say is that we had a very strong momentum towards the end of Q1. And we see no significant differences in the market from that.

Richard Romanius
27:08 - 27:29

And do you still? Assume a slightly lower quarterly. sales revenue compared with before the problems in Spain in order to reach your sales target?

Sofia Heigis
27:30 - 28:18

So when it comes to Spain, as I already mentioned, even though we did see a small step up in March, overall, the quarter was under our expectations and sales are obviously built by volumes. And that's also why I commented on the new important new patient acquisition in Germany, because sales in Q2 will, of course, be influenced by how many new patients you manage to gain in the first quarter. So from that perspective, the first quarter in Spain will have an influence on the second quarter. But we are obviously doing everything we can to catch up and gain many more new patients in the second quarter in Spain. And continuing to build on the strong momentum we saw in both Germany and Italy.

Richard Romanius
28:21 - 28:23

Thanks. I have no more questions.

Sofia Heigis
28:24 - 28:25

Thank you so much.

Operator
28:28 - 28:46

As a reminder, if you wish to ask a question, please dial the pound key on your telephone keypad. There are no more phone questions at this time. So I hand the conference back to the speakers for any written questions and closing comments.

Unknown 1
28:47 - 28:57

Just a few written questions. The first one comes from Rutger, and I think you covered this, Sofia, but maybe worth a recap. How large is the third line market in comparison to the fourth line?

Sofia Heigis
28:58 - 32:03

Thank you for the question. It of course depends on how you are looking at the market. You can look at value market potential overall. You can look at the potential for us to sell Pepaxti. And you can look at it in a number of patients, and at this time point, given that we still, of course, need to secure the regulatory approval and secure market access, we have chosen to look at the market in number of patients and how much sales we can gain from each patient compared to the current label, because those are the facts we have as of today. And then, of course, the potential depends on how many markets we can enter, etc. Et cetera. But if we stay there and look at the big opportunity with this expansion, the number of patients in the third line is approximately double compared to the fourth line. And this is due to that. As I said, multiple myeloma is an aggressive tumor, and there is no cure, and unfortunately, patients are always passing away between the different lines. And that also means that surviving patients become more frail because they have been through yet another line, and their disease is more advanced in the fourth line. And that's the other aspect. So double the number of patients. And then the patients in the third line on average get double the number of treatment cycles. That is, we would sell double the number of vials on each patient if we were to succeed in getting into the third line. So it's obviously much bigger and it's a great opportunity also from the market dynamic, because multiple myeloma is a rare disease. And what we have been struggling with, and what everyone is struggling with is to identify the patients as they are so rare. And in particular, in the largest market, Germany, we have a very scattered market with few patients per prescriber, and they obviously get fewer and fewer per line. If we take an average office-based prescriber in Germany, they may see between 2 to 4 fourth-line patients every year. If we move to the third line, they will have double the number of patients. Hence, it will also be easier for them to identify patients, as they see more of them. And that in itself can of course support potential sales uptake. So there are many different positive aspects of this. And then when it comes to the exact potential, we would like to have more certainty both in terms of regulatory approval, of course, but also from a market access perspective, before we give you specific numbers, and I hope that that is still giving you some more information and some more ability to assess the market.

Unknown 1
32:04 - 32:10

Next question from Tom. Are you still talking to the same company in Japan?

Sofia Heigis
32:11 - 33:38

Yes, we are. So even though we have seen all of these delays, we still have a discussion with what we have called our preferred partner. The delays have been a lot due to their internal processes and how they make decisions, but it has also been due to a couple of restructurings in the company, and that happens a lot. In the pharmaceutical industry, companies tend to restructure their organizations, but it has been unfortunate for us as the teams that we are working with have partly or fully changed. And now we have changed again. So I'm actually going to Japan now in in May to meet the new team and to continue the discussions. But this is obviously slowing us down a bit, and that is why we have said we have a great opportunity, and now we are looking at multiple opportunities with the PDC platform, with all the scientific advancements and a potential expansion in Europe. So that's why we are now also opening up for other discussions to ensure that, at the end of the day, we can conclude the best possible deal as soon as possible, obviously. But it will take some more time. I should be honest to say that at the end of the day, I'm confident that Japanese patients deserve to benefit from Pepaxti and that we should make that happen.

Unknown 1
33:39 - 33:42

That's all the questions. Closing remarks Sofia.

Sofia Heigis
33:42 - 34:09

Yes. So this has been a week of very exciting news and show of positive momentum from Oncopeptides. And I would like to thank all of you out there for listening in today for your continued support. And as we work really, really hard to realize the value for both patients and shareholders in the Oncopeptides team. And by that, I wish you a nice day.

Continue to the webcast
Pierce Group, Audiocast, Q3'26
Language: English11/13/2026, 8:00 AM
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Language: English11/12/2026, 10:00 AM
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 9:00 AM
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Language: English11/12/2026, 8:00 AM
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Language: Swedish11/12/2026, 8:00 AM
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Language: English11/12/2026, 7:15 AM
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Language: English11/11/2026, 1:00 PM
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Language: English11/11/2026, 1:00 PM
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Language: English11/11/2026, 12:30 PM
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Language: English11/10/2026, 5:00 PM
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Language: English11/10/2026, 8:00 AM
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Language: English11/10/2026, 8:00 AM
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Language: Swedish11/6/2026, 9:00 AM
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…